Collectively, these findings suggest that TDO2 upregulation is associated with hepatic steatosis, supporting its potential role as a biomarker or therapeutic target in the context of MASLD. This evidence concerns the gene TDO2 and metabolic dysfunction-associated steatotic liver disease.